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Background: Endovascular thrombectomy improves functional outcome in large vessel 
occlusion ischemic stroke. We examined disability, quality of life, survival and acute care 
costs in the EXTEND-IA trial, which used CT-perfusion imaging selection.
Methods: Large vessel ischemic stroke patients with favorable CT-perfusion were ran-
domized to endovascular thrombectomy after alteplase versus alteplase-only. Clinical 
outcome was prospectively measured using 90-day modified Rankin scale (mRS). 
Individual patient expected survival and net difference in Disability/Quality-adjusted life 
years (DALY/QALY) up to 15 years from stroke were modeled using age, sex, 90-day 
mRS, and utility scores. Level of care within the first 90 days was prospectively measured 
and used to estimate procedure and inpatient care costs (US$ reference year 2014).
results: There were 70 patients, 35 in each arm, mean age 69, median NIHSS 15 
(IQR 12–19). The median (IQR) disability-weighted utility score at 90  days was 0.65 
(0.00–0.91) in the alteplase-only versus 0.91 (0.65–1.00) in the endovascular group 
(p = 0.005). Modeled life expectancy was greater in the endovascular versus alteplase-
only group (median 15.6 versus 11.2 years, p = 0.02). The endovascular thrombectomy 
2Campbell et al. Stroke Thrombectomy QOL and Cost
Frontiers in Neurology | www.frontiersin.org December 2017 | Volume 8 | Article 657
group had fewer simulated DALYs lost over 15 years [median (IQR) 5.5 (3.2–8.7) versus 
8.9 (4.7–13.8), p = 0.02] and more QALY gained [median (IQR) 9.3 (4.2–13.1) versus 
4.9 (0.3–8.5), p = 0.03]. Endovascular patients spent less time in hospital [median (IQR) 
5 (3–11) days versus 8 (5–14) days, p = 0.04] and rehabilitation [median (IQR) 0 (0–28) 
versus 27 (0–65) days, p = 0.03]. The estimated inpatient costs in the first 90 days were 
less in the thrombectomy group (average US$15,689 versus US$30,569, p = 0.008) 
offsetting the costs of interhospital transport and the thrombectomy procedure (average 
US$10,515). The average saving per patient treated with thrombectomy was US$4,365.
conclusion: Thrombectomy patients with large vessel occlusion and salvageable tissue 
on CT-perfusion had reduced length of stay and overall costs to 90 days. There was 
evidence of clinically relevant improvement in long-term survival and quality of life.
clinical Trial registration: http://www.ClinicalTrials.gov NCT01492725 (registered 
20/11/2011).
Keywords: ischemic stroke, thrombolysis, endovascular therapy, mechanical thrombectomy, intraarterial therapy, 
solitaire stent retriever device, cT perfusion, randomized trial
inTrODUcTiOn
Multiple randomized trials have demonstrated improved 
outcomes with endovascular stent thrombectomy compared to 
standard care in patients with ischemic stroke due to large vessel 
occlusion within 6 h of onset (1–6). The effect size was substantial 
with individual patient data meta-analysis indicating a number 
needed to treat (NNT) to improve disability by at least one level 
on the modified Rankin Scale (mRS) of 2.6, and an NNT to 
achieve an extra disability-free outcome of 5 (7).
Disability-adjusted life years (DALY) and quality-adjusted life 
years (QALY) are summative population outcome metrics used 
to describe the impact of stroke recovery and weight the patient’s 
remaining years of life either by the degree of loss of function 
(DALY) or quality of life (QALY) (8). These metrics are often used 
to describe the burden of disease or provide the benefit (effective-
ness) component used in cost-effectiveness evaluations.
Since 2015, several formal cost-effectiveness analyses have 
been published on endovascular stent thrombectomy. A com-
posite of functional outcomes from the MR CLEAN trial and 
US administrative costing data were used in one analysis that 
found endovascular thrombectomy was cost-effective with an 
average US$14,137 per QALY gained and simulations provid-
ing evidence of a 97.6% likelihood of being <US$50,000 per 
QALY over the patients lifetime using a social perspective (9). 
Similarly, in modeling based on the United Kingdom health 
system and data from the initial five positive trials, endovascu-
lar thrombectomy cost an average $11,651 (£7,061) per QALY 
gained over the patient’s lifetime with 100% likelihood of being 
<US$33,000 per QALY using the perspective of the UK National 
Health Service and Personal Social Services (10). Using similar 
data from the five trials but from a Swedish health care payer 
perspective, a small cost saving over the patient’s lifetime and 
improvement by approximately one QALY was demonstrated 
(11). A study based on the SWIFT PRIME trial, which had one 
of the larger treatment effects among the trials, a major cost 
savings over the patient’s lifetime of $23,203 per patient using 
the perspective of the US health care system were reported (12). 
The THRACE trial had a smaller effect size and utilized a short 
1-year time horizon but demonstrated an incremental cost per 
one QALY gained of $14,881 (€13,423) using the perspective of 
the French national health system (13).
A unique feature of the Australian-led EXTEND-IA ran-
domized controlled trial (2) was that all patients were selected 
on the basis of CT perfusion imaging evidence of salvageable 
brain tissue. Endovascular thrombectomy significantly improved 
functional outcome (day 90 mRS) with 71% achieving functional 
independence versus 40% in the alteplase-only group. We aimed 
to estimate the potential impact on resource costs and disability-
adjusted survival benefits of stent thrombectomy compared to 
intravenous thrombolysis alone in patients selected using perfu-
sion imaging.
MaTerials anD MeThODs
In the EXTEND-IA trial, 70 patients were randomized from 10 
hospitals in Australia and New Zealand between August 2012 
and October 2014. The detailed trial protocol (14) and results 
(2) have been published. Briefly, patients were eligible if they 
were receiving intravenous alteplase within 4.5  h of stroke 
onset and had large vessel intracranial occlusion (internal 
carotid or middle cerebral M1 or M2 arteries) and evidence of 
salvageable brain tissue using CT perfusion with irreversibly 
injured ischemic core <70mL (using automated RAPID soft-
ware, Stanford University (15, 16)). Eligibility criteria did not 
specify an upper age limit or any clinical severity limits using 
the National Institutes of Health Stroke Scale (NIHSS) score. 
Patients were randomized 1:1 to endovascular thrombectomy 
with the Solitaire FR device after alteplase versus alteplase alone. 
Functional outcome was assessed using the mRS at 90 days. This 
trial was carried out in accordance with the recommendations of 
the National Statement on Ethical Conduct in Human Research 
TaBle 2 | Average cost per patient by treatment group (US dollars).
resource use and costs alteplase only alteplase + endovascular
Alteplase per patient $3,167 $3,167
Interhospital transfer  
(allowing 75% transferred, 
metropolitan region)a
n/a $573
Endovascular consumablesb n/a $7,327
Endovascular staffingc n/a $2,615
Inpatient care costs $  
(95% CI)
$30,569  
($21,575–$39,564)
$15,689  
($10,774–$20,605)
TOTal $33,736 $29,371
Worst case sensitivity  
analysisd
$24,742 $34,287
Conversion from Australian to United States (US) dollars using 2014 OECD purchasing 
power parity (0.6854) (23).
a75% of cases transferred based on Royal Melbourne Hospital experience, average 
ambulance cost from Ambulance Victoria within metropolitan area US$764, transfers 
from rural areas are more expensive.
b8Fr sheath, microcatheter, guidewires, balloon guide catheter, average 1.1 Solitaire 
devices per patient, groin closure device, and miscellaneous consumables.
cOne neurointerventionist, one neurointerventional fellow, one anesthesiologist, one 
radiographer, and three nurses for 2 h with an extra hour to cover travel time for after 
hours cases and loss of the radiographer and two nurses for 4 h the following day for 
cases after midnight. We allowed for 50% of cases in-hours and 50% out of hours 
(including 10% after midnight) based on the rates at our center.
dWorst-case sensitivity analysis using the lower 95% confidence interval for the mean 
cost in alteplase-only patients and the upper 95% confidence interval for the mean  
cost in endovascular patients.
TaBle 1 | Admission costs per day.
setting cost per day (Us dollars)
Acute stroke unit $1,053
Intensive care unit $133 per hour
Fast stream inpatient rehabilitation $533
Slow stream geriatric rehabilitation $434
Nursing home care/skilled nursing facility $175
Data provided by the Royal Melbourne Hospital Finance Department based on 2014 
costings (22). Conversion from Australian to US dollars using 2014 OECD purchasing 
price power parity (0.6854) (23).
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2007 of the National Health and Medical Research Council of 
Australia with written informed consent from all participants or 
their legal representative in accordance with the Declaration of 
Helsinki. The protocol was approved by the Melbourne Health 
Human Research Ethics Committee.
Average utility values for disability derived from both patient- 
and clinician-based studies have been recently pub lished for 
each level of the mRS: utility was scored 1.0 for mRS = 0; 0.91 
for mRS =  1; 0.76 for mRS =  2; 0.65 for mRS =  3; 0.33 for 
mRS = 4; 0 for mRS = 5; and 0 for mRS = 6 (17). These were 
applied to the mRS at 90 days to compare the level of disability 
between groups. Similarly, QALY benefits were calculated using 
published quality of life utility values for each level of the mRS: 
0.8 for mRS = 0; 0.8 for mRS = 1; 0.65 for mRS = 2; 0.50 for 
mRS = 3; 0.35 for mRS = 4; 0.20 for mRS = 5; and 0 for mRS = 6 
(18). An association between mRS score at 90  days and sub-
sequent mortality rate has been previously demonstrated (19). 
In this study, we extrapolated the expected survival for each 
patient in EXTEND-IA based on the published hazard ratios 
and age- and sex-specific life expectancy drawn from Australian 
Bureau of Statistics life expectancy data for 2013–2015 (20).
Detailed data on length of stay in the acute stroke unit, inpa-
tient fast and slow (“geriatric”) stream rehabilitation, nursing 
home and palliative care were prospectively collected for each 
patient, including home time as the total number of days spent 
home within the first 90 days (21). Costs per day for each level of 
care in the Australian health care system in 2014 (Table 1) were 
supplied by the Royal Melbourne Hospital Finance Department 
(22) and converted to US dollars using the purchasing power 
parity of 68.54 cents per Australian dollar for 2014 (23).
Costs of the endovascular procedure were calculated includ-
ing consumables and staffing as detailed in Table 2. The average 
staffing cost allowed for one neurointerventionist, one neuro-
interventional fellow, one anesthesiologist, one radiographer, 
and three nurses for 2  h with an extra hour to cover travel 
time for after hours cases, and loss of the radiographer and 
two nurses for 4 h the following day for cases after midnight. 
We allowed for 50% of cases in-hours and 50% out of hours 
(including 10% after midnight) based on the rates at our center 
which operated 24 h a day. This more realistically represented 
current clinical practice, in contrast to most other centers 
participating in EXTEND-IA that recruited trial participants 
only during the day.
statistical analysis
Expected survival in the endovascular and alteplase-only groups 
was compared in a Cox regression model censored at 15 years 
post-stroke. Survival estimates were combined with utility values 
(assuming no change in mRS between 3  months and death) 
to evaluate lifetime DALY gained with endovascular versus 
alteplase-only treatment, and the incremental cost-effectiveness 
ratio (ICER) per DALY.
Disability-adjusted life years benefit was calculated with and 
without age-weighting and discounting. Age-weighting reflects a 
view that years lost beyond the age of 63 are of progressively less 
value than those lost during working life. Discounting reduces 
the value of disability-free life by 3% per annum. Currently, the 
World Health Organization (WHO) does not apply age-weight-
ing or discounting for DALY calculations (24). QALY benefit 
is generally not age-weighted but can be discounted. We have 
primarily reported results without age-weighting or discounting 
but provided the alternative combinations, according to standard 
methodology (25), for sensitivity analysis.
Length of stay data were compared between treatment groups 
(Wilcoxon test). The cost of inpatient and nursing home care 
within the first 90 days was calculated for each patient based on 
treatment and bed costs. For sensitivity analysis, a “worst case” 
cost difference was calculated using the upper 95% confidence 
interval for the mean endovascular cost and the lower 95% con-
fidence interval for mean alteplase-only cost.
resUlTs
There were 70 patients randomized (35 in each arm) with mean 
age of 69 (SD 12) years, median NIHSS score 15 (IQR 12–19), 
FigUre 2 | Projected survival modeled over 15 years (using extrapolation 
from 3 months modified Rankin Scale). The adjusted hazard ratio from Cox 
regression model was 0.42 (0.22–0.82), p = 0.01.
FigUre 1 | Boxplots showing length of stay by treatment group. (a) Home 
time (number of days spent at home in the first 90 days post-stroke),  
(B) length of stay in the acute stroke unit, (c) length of stay in inpatient 
rehabilitation.
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and 49% male sex. Detailed patient characteristics were published 
previously and there were no statistically significant imbalances 
(2). At the time of stroke, 24/70 (34%) were aged 65  years or 
younger and in paid employment.
Home time (days spent at home in the first 90  days) was 
increased from median (IQR) 15 (0–69) in the control group to 
73 (47–86) days in the endovascular group, p = 0.001. Length of 
stay in the acute stroke unit was reduced from median (IQR) 8 
(5–14) days in the control group to 5 (3–11) days in the endovas-
cular group (mean 12 versus 8 days), p = 0.04 with no increase 
in intensive care utilization [median (IQR) 0 (0–24) hours in 
control versus 0 (0–4) hours in the endovascular group (mean 11 
versus 9 h), p = 0.51]. Rehabilitation length of stay in survivors 
was reduced from median (IQR) 27 (0–65) days in the control 
group to 0 (0–28) days in the endovascular group (mean 33 versus 
14 days), p = 0.03 with 25% of endovascular patients discharged 
directly home from the acute stroke unit (Figure 1).
Based on the published utility weighting for mRS, the median 
utility score at 90  days was 0.65 (IQR 0–0.91) in the control 
versus 0.91 (IQR 0.65–1) in the endovascular group (unadjusted 
p =  0.005, adjusted for age and baseline NIHSS p =  0.02), an 
increase of approximately one quarter in the total utility range of 
0–1. Based on the 90-day mRS distributions observed, a greater 
median life expectancy in the endovascular versus control group 
(15.6 versus 11.2  years, p =  0.02) was found using long-term 
simulation modeling. In a Cox regression model censored at 
15 years post-treatment and adjusted for age and baseline NIHSS, 
endovascular treatment was associated with reduced risk of death 
(HR 0.42, CI95 0.22–0.82, p = 0.01, Figure 2).
Applying utility scores, median DALYs lost in the endovas-
cular group over the projected lifespan were 5.5 (IQR 3.2–8.7) 
compared to 8.9 (IQR 4.7–13.8) in the control group (p = 0.02, 
adjusted for baseline age and NIHSS) without age-weighting or 
discounting (age-weighted and discounted data in Table 3).
Applying quality of life weighting, median QALYs gained 
in the endovascular group over the projected lifespan were 9.3 
(IQR 4.2–13.1) compared to 4.9 (IQR 0.3–8.5) in control group 
TaBle 3 | Disability-adjusted life years (DALY) lost and Quality-adjusted life years (QALY) gained in endovascular versus alteplase-only groups calculated with and 
without age-weighting and discounting.
Median years (iQr) endovascular  
versus alteplase-only
p-Value Worst-case 
icer (Us 
dollars)Unadjusted adjusted for age and 
baseline nihss
DalY lost
Not discounted not age-weighted 5.5 (3.2–8.7) versus 8.9 (4.7–13.8)  
(mean difference 2.72)
0.04 0.02 $3,509
Discounted not age-weighted
3.2 (1.9–6.2) versus 6.3 (2.9–10.5)  
(mean difference 2.34)
0.02 0.02
$4,079
Not discounted age-weighted 
2.3 (1.6–5.0) versus 4.1 (2.2–7.5)  
(mean difference 1.45)
0.07 0.02
$6,583
Discounted age-weighted 
2.0 (0.94–3.6) versus 3.5 (1.6–5.8)  
(mean difference 1.27)
0.03 0.02
$7,516
QalY gained
Not discounted 9.3 (4.2–13.1) versus 4.9 (0.3–8.3)  
(mean difference 3.29)
0.01 0.03 $2,901
Discounted 7.5 (2.7–10.2) versus 4.0 (0.3–6.9)  
(mean difference 2.50)
0.01 0.03
$3,818
Worst-case incremental cost-effectiveness ratios (ICER) based on upper 95% confidence interval for endovascular cost and lower 95% confidence interval for alteplase-only cost.
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(p = 0.03, adjusted for baseline age and NIHSS) without discount-
ing (discounted data in Table 3).
The average cost of inpatient care in the first 90  days was 
estimated to be US$14,880 less for endovascular compared to 
control patients (p =  0.008), with the average per patient cost 
US$4,365 less in the endovascular group after accounting for 
inter-hospital transfers and thrombectomy procedural costs 
(Table  2). Therefore, endovascular therapy was determined to 
be cost-saving (or “dominant” in health-economic terms) in this 
context. Ongoing nursing care (US$70,000 p.a.) was required 
for 0/35 endovascular and 5/35 (14%) alteplase-only patients 
(p = 0.054).
In sensitivity analyses, the “worst case” additional cost of 
endovascular thrombectomy was US$9,545 which generated 
an ICER of US$3,509 to US$7,516 per DALY lost depending 
on whether age-weighting and discounting were applied; and 
US$2,901 to $US3,818 per QALY gained depending on whether 
discounting was applied (Table 3).
DiscUssiOn
In patients with ischemic stroke due to proximal cerebral arterial 
occlusion who had salvageable tissue on CT-perfusion imaging, 
endovascular thrombectomy combined with intravenous alteplase 
reduced disability and length of stay within the first 90  days 
compared with alteplase alone. Overall, healthcare utilization was 
reduced leading to estimated cost savings by 90 days. Based on 
simulation modeling of 90-day mRS scores, Australian life table 
data, and expected mortality rates by mRS category, a sustained 
and statistically significant mortality benefit up to 15  years 
post-treatment was found with associated benefits in DALYs lost 
and QALYs gained. On average, endovascular thrombectomy 
saved approximately two DALYs over the patient’s lifetime and 
US$4,365 per patient within the first 90 days. The worst case ICER 
of US$7,516 per DALY or US$3,818 per QALY is well within the 
$50,000 “willingness to pay” criterion often applied. This sensi-
tivity analysis using the most pessimistic endovascular and opti-
mistic alteplase-only costing suggests robust cost-effectiveness, as 
supported by other studies that demonstrated cost-effectiveness 
and, in many cases, cost savings with endovascular thrombec-
tomy (9–13). Given the substantially greater level of disability in 
the alteplase-only group, the costs of care beyond 90 days, which 
were not included in this analysis, would be expected to remain 
greater than in the endovascular group.
EXTEND-IA had the largest absolute benefit of endovascular 
therapy of the published trials, likely due to rapid and effective 
revascularization combined with perfusion imaging selection 
to exclude patients with large areas of irreversibly injured brain. 
However, the relative risk of independent outcome was very simi-
lar among all the stent retriever trials (26). Therefore, although 
costs of care for the endovascular group in other trials may be 
greater, there would also likely be an increase in the costs of care 
for the control group.
Strengths of our study include the prospective design nested 
within a randomized controlled trial that utilized a standard-
ized selection and treatment protocol. Limitations include 
the relatively small sample size introducing imprecision to 
our estimates. However, EXTEND-IA prospectively collected 
length of stay data and the effect size was sufficient to provide 
statistically robust results. Costs of care were estimated based on 
utilization of bed-days or ICU hours with fixed costs for these 
from one large Australian hospital that contributed the majority 
of cases. In reality, individual patients with similar number of 
bed days may require different intensity of management with 
medications, imaging, pathology, nursing and allied health 
interventions which, depending on the local payment system, 
may lead to variation in true patient costs. Our quality of life 
weights were based on published averages for mRS categories 
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